About us

The Early Years: 1920s and ’40s

Angelini’s story started in 1919 in Ancona, in central Italy, in a small laboratory where Francesco Angelini began his ascent in the world of pharmaceutical industry. In 1940 Francesco Angelini founded A.C.R.A.F., which stands for Aziende Chimiche Riunite Angelini Francesco. ACRAF’s main activities were still at this time the manufacture and distribution of pharmaceuticals.
In the immediate post-war years, Francesco Angelini was the first to import Vitamin B12 – a tonic used in the treatment of anaemia, a condition which was very widespread at the time – into Italy. The vitamin, which was manufactured and marketed under the Dobetin brand name, met with great enthusiasm and was Angelini’s first major success.


The 1950s: The Turning Point

During the 1950s, Francesco Angelini consolidated his activity and began to shape his business along more industrial lines. With his son Igino, Francesco Angelini decided at the beginning of the 1950s to expand his operation to Rome, where the Company’s headquarters is still located. During this period the Company also diversified and Angelini entered the consumer packaged goods market: in 1958, Francesco Angelini set up Fater, a Pescara-based company that manufactures babies’ nappies and women’s sanitary towels. In the same year, the Company launched Tachipirina, a paracetamol-based flu drug that is Italy’s most widely prescribed children’s medicine and - in absolute terms - one of the three biggest-selling pharmaceuticals in Italy.


The 1960s and ’70s: the “Golden Age”

In 1963, right in the middle of Italy’s baby-boom, Fater was the first Italian company to launch disposable nappies under the Lines brand. Two years later, the Company manufactured its first line of sanitary towels (again under the Lines brand). This brand name was chosen because it evokes linen, the material used at that time to make these sanitary products. In 1964, the year of Francesco Angelini’s death, his soon Igino took the helm of the Company.
In the 1960s Angelini began to manufacture the first chemical compounds to originate from in-house pharmaceutical research. Between the ’60s and ’70s, Angelini discovered and developed a number of important, innovative molecules. These included oxolamine (cough suppressant), benzydamine (anti-inflammatory), trazodone (anti-depressant) and dapiprazole (antiglaucoma).
In the manufacturing technology field, in 1975 Angelini was the first Italian company to introduce nappy-manufacturing machinery and was one of the first to use computer-aided design and computerised systems in its production lines.


The 1980s: A Modern, International Company

In 1985 Angelini grasped the potential of the pain reliever ibuprofen in Italy and launched an OTC headache remedy under the brand name Moment. This was the first example in Italy of marketing applied to pharmaceuticals. Indeed, Igino Angelini had been convinced as early as the 1960s of the importance of communication for the success of pharmaceuticals and parapharmaceuticals.
During the ’80s, the Angelini Group began its expansion into the international market with the creation of manufacturing facilities and commercial structures in Spain and Portugal. The Angelini Group began operating in the Iberian peninsula in 1979, when it acquired the Barcelona-based Lepori Group, which consisted of three companies: Farma Lepori and L. Lepori, which manufactured and marketed pharmaceuticals, and Laboratorios Ausonia, which specialised in the manufacturing of talc and children’s products. .


The 1990s: Diversification and Strategic Alliances

In 1993, after the death of Igino Angelini, his son Francesco took the reins and further consolidated the Group’s position in the health and hygiene sector by strengthening its alliance with Procter&Gamble, which dates from 1992. In Italy, the American multinational is engaged in the marketing of the international Pampers brand (babies’ nappies) alongside Lines, for women’s sanitary towels, while the Lines nappy brand was licensed to another industrial group for antitrust reasons.
In the mid-1990s, with a view of diversifying the corporate business activities, Francesco Angelini reinforced the agri-food division set up at the end of the ’50s with Isea, a company manufacturing quality seed products. In 1993 Angelini also entered the quality wine, oil and cold-meat market.


From 2000: Core Business Consolidation and Internationalisation

Angelini has been one of Italy’s leading manufacturers and distributors of generics since 2000. That same year, Amuchina, the Genoa-based company that manufactures sanitizing products and the disinfectant of the same name, joined the Angelini Group, thereby expanding its portfolio of parapharmaceuticals.
In 2000-2001, the Angelini Group strengthened its international position. The acquisition of Helsinn Produtos Farmacêuticos and Helfarma Produtos Farmacêuticos, two Portuguese pharmaceutical manufacturers, consolidated Angelini’s presence in Spain and Portugal. The two companies are now called ‘Angelini Farmacêutica’ and ‘Angenérico, Produtos Farmacêuticos Genéricos’ respectively.
In 2002, Angelini purchased Farmamed, one of Italy’s leading companies in the marketing of mass-marketed parapharmaceuticals. In 2003, the Group also established a foothold in the ‘plant remedy’ and ‘nutritional supplement’ market with the acquisition of Body Spring.
In recent years, through commercial and partnership agreements, Angelini has been preparing the ground for development in other countries too. In 2004, the Angelini Group acquired a significant holding in Elder Pharma, a pharmaceutical company that comes 32nd out of 2,500 companies operating in the Indian market. In 2007 Angelini acquired Csc Pharmaceuticals, a group which operates in Eastern Europe and which was a strategical partner for Angelini since 1998. In 2008 Angelini acquired the greek pharmaceuticals group Faran.
Angelini was also one of the first companies to register molecules at the European level through the Mutual Recognition Procedure, with Italy as Reference Member State. Since 2000 about 50 registrations have been lodged in 19 European countries, mainly for chemical compounds manufactured through in-house research, such as benzydamine and prulifloxacin.


Products & Medicines